GCL1815 shows cold prevention promise Induces Two Types of Dendritic Cell Activation and Effectively Suppresses Onset of the Common Cold: A Randomized, Double-Blind, Placebo-Controlled Trial.
Moderately relevant findings
We aimed to understand if GCL1815, a specific lactic acid bacterium, could play a role in preventing common colds. In a well-structured study, two hundred participants were split into two groups—one taking GCL1815 capsules and the other a placebo—for eight weeks. It was a double-blind setup, meaning neither the participants nor the researchers knew who was receiving the treatment, helping to eliminate bias.
Our findings were quite promising. Those taking GCL1815 reported a lower incidence of common cold symptoms like feverishness and runny nose compared to the placebo group. Specifically, significant changes were observed in two types of dendritic cells in the GCL1815 group, which are crucial for our immune response. This suggests that GCL1815 not only activates these cells but might also enhance our body’s ability to fight off viruses that cause colds.
Overall, this insight points to the potential of GCL1815 in bolstering immune defenses against common colds, offering a potential preventive measure for those concerned about seasonal sniffles. While more research could clarify the exact mechanisms at play, these results hint at an exciting avenue for common cold prevention through dietary means.
Read More
KT-11 may support immune healthSupplementation with heat-sterilized Lactobacillus crispatus strain KT-11 stimulates the T cell-related immune function of healthy Japanese adults: A pilot randomized, placebo-controlled, double-blind, parallel-group study.
Moderate relevance for cold treatment
We conducted a study to see if heat-sterilized Lactobacillus crispatus strain KT-11 could boost immune function in healthy individuals, particularly in relation to common cold symptoms.
For four weeks, 22 healthy adults took either KT-11 or a placebo. We assessed their immune cell counts and overall immune health, while also tracking any cold-like symptoms they experienced. In the end, we analyzed results from 20 participants who completed the trial.
Those who took KT-11 had a notable increase in a type of immune cell known as CD3 T cells. Interestingly, women in the group showed a rise in a specific subgroup of T cells linked to immune response. Although we did not see any changes in antibodies against SARS-CoV-2, participants taking KT-11 reported feeling fewer cold-like symptoms, particularly fatigue.
This pilot study gives us insight into how KT-11 might influence immune cell profiles, hinting that further research on this topic could be worthwhile.
Read More